Thermo Fisher Scientific has unveiled the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to advance precision medicine.
The assay is designed to identify a wide array of genomic alterations across 517 genes.
Building on the Ion Torrent technology and streamlined, automated workflows, the assay promises to deliver comprehensive genomic profiling (CGP) results by the next day.
CGP enables the simultaneous examination of numerous biomarkers in a single test, providing timely insights into oncogenic drivers.
Previously available on the Ion GeneStudio S5 systems, the Oncomine Comprehensive Assay Plus identifies single-nucleotide variants, insertions and deletions, copy number variations, and fusions.
It also detects genomic signatures such as homologous recombination deficiency (HRD), tumour mutational burden (TMB), and microsatellite instability (MSI).
The Genexus System enhances these capabilities, allowing researchers to quickly and easily identify a broad spectrum of critical biomarkers.
Thermo Fisher Scientific clinical next generation sequencing president Kathy Davy said: “In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development.
“The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.”
The Genexus System is an automated, integrated next-generation sequencing (NGS) platform capable of delivering results by the next day.
Its end-to-end automation reduces hands-on time, making genomic profiling more accessible to researchers with varying expertise levels.
Research teams can use the Oncomine Comprehensive Assay Plus, now available on the Genexus System, to obtain accurate and robust CGP results promptly.
Imagene Health founder Hector M Alcaraz said: “We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI, and HRD.
“This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.”
